Nanjing Sanhome Pharmaceutical Co., Ltd.

Xu Quan

Yong Wang

Liwen Zhao

Hai Feng Wang

Hai Jun Wang

Yazhou Wang

Chao Li

Guochuang Zheng

Qi Liu

Chen Wang

Hongyan Chen

Chunhuan Jiang

Shengwei Yang

Wei Sun

Qiqi Shi

Tingting Yang

Kangning Zhan

Menghua Chen

Yexin Liao

Hai Wang

The present invention belongs to the field of medicinal chemistry and relates to a class of substituted tricyclic compounds as PRMT5 inhibitors and the use thereof. Specifically, the present invention provides a compound represented by formula (A) or an isomer, pharmaceutically acceptable salt, solvate, crystal or prodrug thereof, a preparation method therefor, a pharmaceutical composition containing the compounds, and the use of the compounds or the composition for treating a disease mediated by PRMT5. The compounds of the present invention show significant inhibitory activity on PRMT5.

Substituted tricyclic compound as PRMT5 inhibitor and use thereof

Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, and methods for preparing the same, and pharmaceutical compositions comprising the compounds and the use of the compounds or compositions for treating and/or preventing diseases associated with ACC expression, such as fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. The compound has a good inhibitory activity against ACC and shows good promise to be a therapeutic drug for fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. 

Compound as ACC inhibitor and use thereof

Growing community of inventors

Jiangsu, China

Xu Quan